VacV Biotherapeutics
Developing oncolytic viruses as therapeutics for cancer
Developing oncolytic viruses as therapeutics for cancer
VacV Biotherapeutics, with the slogan "Developing oncolytic viruses as therapeutics for cancer," is a UK-based startup founded in 2022. The company, led by cancer immunotherapy experts Professor Yaohe Wang, Professor Nicholas Lemoine, Dr. Louisa Chard Dunmall, and Dr. Peng Liu, is focused on developing innovative viral-based therapies for cancers. Their unique approach is based on the Vaccinia virus, which aims to stimulate a patient’s immune system to fight cancer while simultaneously destroying cancer cells. This cutting-edge approach offers advantages over existing immunotherapies, including minimized toxicity, higher specificity, and efficacy, allowing for efficient systemic delivery of an immunotherapy for the first time. VacV Biotherapeutics recently secured a $3.00M Seed Round investment on 01 January 2022 led by Proxima Ventures. The startup operates in the biotechnology, health care, and life sciences industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $3.00M | 1 |
|
01 Jan 2022 |
No recent news or press coverage available for VacV Biotherapeutics.
We care about your data, and we'd love to use cookies make your experience better.